Our laboratory developed a recombinant human monoclonal IgM antibody, rHIgM22, which binds specifically to live oligodendrocytes and myelin and promotes remyelination in mouse models of MS [12–14]. This evidence concerns the gene CD40LG and myeloid sarcoma.